FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208441607> ?p ?o ?g. }

• W3208441607 endingPage "1580" @default.
• W3208441607 startingPage "1569" @default.
• W3208441607 abstract "BackgroundAsthma is the most common chronic disease in children globally. The Global Asthma Network (GAN) Phase I study aimed to determine if the worldwide burden of asthma symptoms is changing.MethodsThis updated cross-sectional study used the same methods as the International study of Asthma and Allergies in Childhood (ISAAC) Phase III. Asthma symptoms were assessed from centres that completed GAN Phase I and ISAAC Phase I (1993–95), ISAAC Phase III (2001–03), or both. We included individuals from two age groups (children aged 6–7 years and adolescents aged 13–14 years) who self-completed written questionnaires at school. We estimated the 10-year rate of change in prevalence of current wheeze, severe asthma symptoms, ever having asthma, exercise wheeze, and night cough (defined by core questions in the questionnaire) for each centre, and we estimated trends across world regions and income levels using mixed-effects linear regression models with region and country income level as confounders.FindingsOverall, 119 795 participants from 27 centres in 14 countries were included: 74 361 adolescents (response rate 90%) and 45 434 children (response rate 79%). About one in ten individuals of both age groups had wheeze in the preceding year, of whom almost half had severe symptoms. Most centres showed a change in prevalence of 2 SE or more between ISAAC Phase III to GAN Phase I. Over the 27-year period (1993–2020), adolescents showed a significant decrease in percentage point prevalence per decade in severe asthma symptoms (–0·37, 95% CI –0·69 to –0·04) and an increase in ever having asthma (1·25, 0·67 to 1·83) and night cough (4·25, 3·06 to 5·44), which was also found in children (3·21, 1·80 to 4·62). The prevalence of current wheeze decreased in low-income countries (–1·37, –2·47 to –0·27], in children and –1·67, –2·70 to –0·64, in adolescents) and increased in lower-middle-income countries (1·99, 0·33 to 3·66, in children and 1·69, 0·13 to 3·25, in adolescents), but it was stable in upper-middle-income and high-income countries.InterpretationTrends in prevalence and severity of asthma symptoms over the past three decades varied by age group, country income, region, and centre. The high worldwide burden of severe asthma symptoms would be mitigated by enabling access to effective therapies for asthma.FundingInternational Union Against Tuberculosis and Lung Disease, Boehringer Ingelheim New Zealand, AstraZeneca Educational Grant, National Institute for Health Research, UK Medical Research Council, European Research Council, and Instituto de Salud Carlos III. Asthma is the most common chronic disease in children globally. The Global Asthma Network (GAN) Phase I study aimed to determine if the worldwide burden of asthma symptoms is changing. This updated cross-sectional study used the same methods as the International study of Asthma and Allergies in Childhood (ISAAC) Phase III. Asthma symptoms were assessed from centres that completed GAN Phase I and ISAAC Phase I (1993–95), ISAAC Phase III (2001–03), or both. We included individuals from two age groups (children aged 6–7 years and adolescents aged 13–14 years) who self-completed written questionnaires at school. We estimated the 10-year rate of change in prevalence of current wheeze, severe asthma symptoms, ever having asthma, exercise wheeze, and night cough (defined by core questions in the questionnaire) for each centre, and we estimated trends across world regions and income levels using mixed-effects linear regression models with region and country income level as confounders. Overall, 119 795 participants from 27 centres in 14 countries were included: 74 361 adolescents (response rate 90%) and 45 434 children (response rate 79%). About one in ten individuals of both age groups had wheeze in the preceding year, of whom almost half had severe symptoms. Most centres showed a change in prevalence of 2 SE or more between ISAAC Phase III to GAN Phase I. Over the 27-year period (1993–2020), adolescents showed a significant decrease in percentage point prevalence per decade in severe asthma symptoms (–0·37, 95% CI –0·69 to –0·04) and an increase in ever having asthma (1·25, 0·67 to 1·83) and night cough (4·25, 3·06 to 5·44), which was also found in children (3·21, 1·80 to 4·62). The prevalence of current wheeze decreased in low-income countries (–1·37, –2·47 to –0·27], in children and –1·67, –2·70 to –0·64, in adolescents) and increased in lower-middle-income countries (1·99, 0·33 to 3·66, in children and 1·69, 0·13 to 3·25, in adolescents), but it was stable in upper-middle-income and high-income countries. Trends in prevalence and severity of asthma symptoms over the past three decades varied by age group, country income, region, and centre. The high worldwide burden of severe asthma symptoms would be mitigated by enabling access to effective therapies for asthma." @default.
• W3208441607 created "2021-11-08" @default.
• W3208441607 creator A5000572985 @default.
• W3208441607 creator A5001320822 @default.
• W3208441607 creator A5001331614 @default.
• W3208441607 creator A5001653109 @default.
• W3208441607 creator A5002710521 @default.
• W3208441607 creator A5003298706 @default.
• W3208441607 creator A5003373914 @default.
• W3208441607 creator A5006249149 @default.
• W3208441607 creator A5008582535 @default.
• W3208441607 creator A5008718320 @default.
• W3208441607 creator A5010088725 @default.
• W3208441607 creator A5010832382 @default.
• W3208441607 creator A5012104141 @default.
• W3208441607 creator A5012477354 @default.
• W3208441607 creator A5013262312 @default.
• W3208441607 creator A5013368617 @default.
• W3208441607 creator A5013468466 @default.
• W3208441607 creator A5015182418 @default.
• W3208441607 creator A5015599654 @default.
• W3208441607 creator A5016371253 @default.
• W3208441607 creator A5016646185 @default.
• W3208441607 creator A5017646350 @default.
• W3208441607 creator A5022668687 @default.
• W3208441607 creator A5023025863 @default.
• W3208441607 creator A5023211986 @default.
• W3208441607 creator A5023495576 @default.
• W3208441607 creator A5024910650 @default.
• W3208441607 creator A5025905394 @default.
• W3208441607 creator A5029714577 @default.
• W3208441607 creator A5031866330 @default.
• W3208441607 creator A5034866415 @default.
• W3208441607 creator A5039052795 @default.
• W3208441607 creator A5039757066 @default.
• W3208441607 creator A5044944933 @default.
• W3208441607 creator A5047620786 @default.
• W3208441607 creator A5049974329 @default.
• W3208441607 creator A5052676254 @default.
• W3208441607 creator A5052847780 @default.
• W3208441607 creator A5054538874 @default.
• W3208441607 creator A5056556051 @default.
• W3208441607 creator A5057142514 @default.
• W3208441607 creator A5059998788 @default.
• W3208441607 creator A5060732016 @default.
• W3208441607 creator A5062976290 @default.
• W3208441607 creator A5063379693 @default.
• W3208441607 creator A5066272602 @default.
• W3208441607 creator A5069066159 @default.
• W3208441607 creator A5070823234 @default.
• W3208441607 creator A5072539089 @default.
• W3208441607 creator A5073227636 @default.
• W3208441607 creator A5074345456 @default.
• W3208441607 creator A5074962636 @default.
• W3208441607 creator A5077805196 @default.
• W3208441607 creator A5077828631 @default.
• W3208441607 creator A5078005779 @default.
• W3208441607 creator A5078165893 @default.
• W3208441607 creator A5079043109 @default.
• W3208441607 creator A5081049016 @default.
• W3208441607 creator A5082100663 @default.
• W3208441607 creator A5082417044 @default.
• W3208441607 creator A5083472606 @default.
• W3208441607 creator A5083818971 @default.
• W3208441607 creator A5085682137 @default.
• W3208441607 creator A5087205628 @default.
• W3208441607 creator A5088787760 @default.
• W3208441607 date "2021-10-01" @default.
• W3208441607 modified "2023-10-18" @default.
• W3208441607 title "Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study" @default.
• W3208441607 cites W1479782256 @default.
• W3208441607 cites W1567692140 @default.
• W3208441607 cites W2015795623 @default.
• W3208441607 cites W2075082837 @default.
• W3208441607 cites W2098082628 @default.
• W3208441607 cites W2108344016 @default.
• W3208441607 cites W2120793327 @default.
• W3208441607 cites W2126765063 @default.
• W3208441607 cites W2142010704 @default.
• W3208441607 cites W2145071473 @default.
• W3208441607 cites W2153384298 @default.
• W3208441607 cites W2406434878 @default.
• W3208441607 cites W2527824850 @default.
• W3208441607 cites W2561808084 @default.
• W3208441607 cites W2583968762 @default.
• W3208441607 cites W2751792491 @default.
• W3208441607 cites W2751884637 @default.
• W3208441607 cites W2899736836 @default.
• W3208441607 cites W2902915599 @default.
• W3208441607 cites W2904556803 @default.
• W3208441607 cites W2912654919 @default.
• W3208441607 cites W2924144276 @default.
• W3208441607 cites W3089128525 @default.
• W3208441607 cites W3098203414 @default.
• W3208441607 cites W3121923724 @default.
• W3208441607 cites W3132897233 @default.
• W3208441607 cites W4229874197 @default.
• W3208441607 doi "https://doi.org/10.1016/s0140-6736(21)01450-1" @default.

• next